Cochrane · systematic review · CD010885
Different infusion durations for preventing platinum‐induced hearing loss in children with cancer
van As, JW, van den Berg, H, van Dalen, EC · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
3
No studies
4
Included studies
NR
No studies 4 · 57.1%Ungraded 0 · 0%Very low 0 · 0%Low 3 · 42.9%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyContinuous platinum infusion compared to bolus platinum infusion for children with cancer treated with platinum‐based therapy
Population: children with cancer treated with platinum‐based therapy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Hearing loss (asymptomatic and symptomatic disease according to Brock criteria) exact instrument used to test hearing loss was not reported Continuous platinum infusion vs bolus platinum infusion | RR 1.39 [0.47, 4.13] | 1 study · 67 participants | Low Downgraded: risk of bias |
Tinnitus ‐ not reported Continuous platinum infusion vs bolus platinum infusion | no estimate extracted | NR | No studies |
Overall survival ‐ not reported Continuous platinum infusion vs bolus platinum infusion | no estimate extracted | NR | No studies |
Event‐free survival ‐ not reported Continuous platinum infusion vs bolus platinum infusion | no estimate extracted | NR | No studies |
Tumour response (complete or partial remission according to INRC) Continuous platinum infusion vs bolus platinum infusion | no estimate extracted | 1 study · 1 participants | Low |
Adverse effects: toxic death (no definition provided) Continuous platinum infusion vs bolus platinum infusion | RR 1.12 [0.07, 17.31] | 1 study · 91 participants | Low |
Quality of life ‐ not reported Continuous platinum infusion vs bolus platinum infusion | no estimate extracted | NR | No studies |
Continuous platinum infusion compared to bolus platinum infusion for children with cancer treated with platinum‐based therapy
Population: children with cancer treated with platinum‐based therapy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Hearing loss (asymptomatic and symptomatic disease according to Brock criteria) exact instrument used to test hearing loss was not reported Continuous platinum infusion vs bolus platinum infusion | RR 1.39 [0.47, 4.13] | 1 study · 67 participants | Low Downgraded: risk of bias |
Tinnitus ‐ not reported Continuous platinum infusion vs bolus platinum infusion | no estimate extracted | NR | No studies |
Overall survival ‐ not reported Continuous platinum infusion vs bolus platinum infusion | no estimate extracted | NR | No studies |
Event‐free survival ‐ not reported Continuous platinum infusion vs bolus platinum infusion | no estimate extracted | NR | No studies |
Tumour response (complete or partial remission according to INRC) Continuous platinum infusion vs bolus platinum infusion | no estimate extracted | 1 study · 1 participants | Low |
Adverse effects: toxic death (no definition provided) Continuous platinum infusion vs bolus platinum infusion | RR 1.12 [0.07, 17.31] | 1 study · 91 participants | Low |
Quality of life ‐ not reported Continuous platinum infusion vs bolus platinum infusion | no estimate extracted | NR | No studies |
Continuous platinum infusion compared to bolus platinum infusion for children with cancer treated with platinum‐based therapy
Population: children with cancer treated with platinum‐based therapy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Hearing loss (asymptomatic and symptomatic disease according to Brock criteria) exact instrument used to test hearing loss was not reported Continuous platinum infusion vs bolus platinum infusion | RR 1.39 [0.47, 4.13] | 1 study · 67 participants | Low Downgraded: risk of bias |
Tinnitus ‐ not reported Continuous platinum infusion vs bolus platinum infusion | no estimate extracted | NR | No studies |
Overall survival ‐ not reported Continuous platinum infusion vs bolus platinum infusion | no estimate extracted | NR | No studies |
Event‐free survival ‐ not reported Continuous platinum infusion vs bolus platinum infusion | no estimate extracted | NR | No studies |
Tumour response (complete or partial remission according to INRC) Continuous platinum infusion vs bolus platinum infusion | no estimate extracted | 1 study · 1 participants | Low |
Adverse effects: toxic death (no definition provided) Continuous platinum infusion vs bolus platinum infusion | RR 1.12 [0.07, 17.31] | 1 study · 91 participants | Low |
Quality of life ‐ not reported Continuous platinum infusion vs bolus platinum infusion | no estimate extracted | NR | No studies |
Continuous platinum infusion compared to bolus platinum infusion for children with cancer treated with platinum‐based therapy
Population: children with cancer treated with platinum‐based therapy
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Hearing loss (asymptomatic and symptomatic disease) exact test method not reported Continuous platinum infusion vs bolus platinum infusion | RR 1.39 [0.47, 4.13] | 1 study · 67 participants | Low Downgraded: risk of bias |
Tinnitus ‐ not reported Continuous platinum infusion vs bolus platinum infusion | no estimate extracted | NR | No studies |
Overall survival ‐ not reported Continuous platinum infusion vs bolus platinum infusion | no estimate extracted | NR | No studies |
Event‐free survival ‐ not reported Continuous platinum infusion vs bolus platinum infusion | no estimate extracted | NR | No studies |
Tumour response (complete or partial remission) Continuous platinum infusion vs bolus platinum infusion | no estimate extracted | 1 study · 1 participants | Low Downgraded: risk of bias |
Adverse effects: toxic death (no definition provided) Continuous platinum infusion vs bolus platinum infusion | RR 1.12 [0.07, 17.31] | 1 study · 91 participants | Low Downgraded: risk of bias |
Quality of life ‐ not reported Continuous platinum infusion vs bolus platinum infusion | no estimate extracted | NR | No studies |